The BARF Project: A Pilot Study Using the BARF Scale to Assess CINV in Children

Not Applicable

Terminated

• Conditions: Nausea

• Registration Number: NCT04678947
• Lead Sponsor: Washington University School of Medicine

Brief Summary

In this pilot study, the Baxter Retching Faces (BARF) Scale will be used to assess chemotherapy induced nausea and vomiting (CINV) in the pediatric cancer population during chemotherapy admissions, and the corresponding administration of anti-emetic medications will be reviewed.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-12-16
• Study First Submitted QC: 2020-12-16
• Study First Posted: 2020-12-22
• Study Start: 2021-03-17
• Primary Completion: 2021-03-25
• Study Completion: 2021-03-25
• Status Verified: 2021-11
• Last Update Submitted: 2021-11-09
• Last Update Posted: 2021-11-17

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

• Patients diagnosed with cancer of any kind.
• Patients receiving inpatient chemotherapy at SLCH on the general pediatric oncology service
• Patients admitted for a course of inpatient chemotherapy scheduled to last at least 24 hours and but no more than 7 days.
• Patients who have received any prior cancer treatment, including radiation therapy, and/or surgery.
• Patients ages 4 to 12 years of age.
• Patient with a guardian who has the ability to understand English and the willingness to sign an IRB approved written informed consent document.

Exclusion Criteria

• Any patient who is not undergoing inpatient chemotherapy on the general pediatric oncology service, including patients undergoing chemotherapy as conditioning for hematopoietic stem cell transplantation or other cellular therapy.
• Any patient who is receiving their first cycle of inpatient chemotherapy (however, they can be included during a future cycle).
• Any patient who is blind or unable to communicate by speaking or pointing.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Doses of anti-emetic medication administered during inpatient chemotherapy admissions	24 hours - 7 days (estimated)

Trial Locations

Locations (1)

Washington University School of Medicine; 🇺🇸 Saint Louis, Missouri, United States